The coagulation factors differ in the minimum quantity needed for hemostasis.
|
Coagulation Factor |
Minimum Hemostasis |
Need in Major Surgery |
Half-Life |
|
Factor 1 |
50 - 100 mg/dL |
> 100 mg/dL |
3 - 6 day |
|
Factor 2 |
10 - 20% |
30 - 40% |
50 - 80 hours |
|
Factor 5 |
5 - 15% |
25% |
4.5 - 36 hours |
|
Factor 7 |
5 - 10% |
10 - 20% |
2 - 5 hours |
|
Factor 8-AHF |
1 - 5% |
50 - 60% |
8 - 12 hours |
|
Factor 8-VWR |
25% |
25% |
24 hours |
|
Factor 9 |
10 - 20% |
50 - 60% |
18 - 24 hours |
|
Factor 10 |
5 - 10% |
15 - 20% |
20 - 42 hours |
|
Factor 11 |
10 - 15% |
15 - 30% |
40 - 80 hours |
|
Factor 12 |
< 10% |
10% |
50 hours |
|
Factor 13 |
1% |
5% |
7 - 14 days |
1 unit of a coagulation factor is the factor activity present in 1 mL of normal male plasma; this is considered 100% of normal activity. Plasma levels also may be given in units per dL, with 100 units/dL equivalent to 1 unit/mL
Fibrinogen half-life is markedly reduced in fibrinolytic states.
Treatment of von Willebrand's disease requires replacement of both Factor 8-AHF (procoagulant) and Factor 8-VWF. Factor 8 concentrates supply the former but not the latter, so that cryoprecipitate is the product of choice in replacement therapy.
Usually factor 12 deficiency does not require replacement therapy.
Factor Content of Plasma Products
|
|
FFP |
Cryoprecipitate |
|
Volume |
250 mL |
20 mL |
|
Factor 1 content |
500 mg |
200 mg |
|
Factor 2 content |
225 U |
|
|
Factor 5 content |
225 U |
|
|
Factor 7 content |
225 U |
|
|
Factor 8-AHF content |
225 U |
90 U |
|
Factor 8-VWF content |
225 U |
90 U |
|
Factor 9 content |
225 U |
|
|
Factor 10 content |
225 U |
|
|
Factor 11 content |
225 U |
|
|
Factor 12 content |
225 U |
|
|
Factor 13 content |
225 U |
90 U |
where:
• "U" indicates "unit of activity", as described above
Specialty: Hematology Oncology, Clinical Laboratory, Clinical Laboratory, Pharmacology, clinical
